Pfizer Inc. (NYSE:PFE) Shares Sold by Sentry Investment Management LLC

Sentry Investment Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 46.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,650 shares of the biopharmaceutical company’s stock after selling 15,131 shares during the quarter. Sentry Investment Management LLC’s holdings in Pfizer were worth $508,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Worth Asset Management LLC purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer in the 3rd quarter valued at $30,000. Sanctuary Wealth Management L.L.C. purchased a new position in shares of Pfizer in the 4th quarter valued at $50,000. Mizuho Securities Co. Ltd. purchased a new position in shares of Pfizer in the 3rd quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on PFE shares. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE opened at $25.88 on Tuesday. The company has a market cap of $146.55 billion, a price-to-earnings ratio of 71.94, a PEG ratio of 1.16 and a beta of 0.61. The firm’s 50-day simple moving average is $27.27 and its 200-day simple moving average is $28.84. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a fifty-two week low of $25.61 and a fifty-two week high of $41.33.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.14 earnings per share. As a group, equities research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.